- Dual-listed biopharmaceutical company Immuron Limited has entered a new research agreement with Monash University.
- The agreement will focus on advancing the SARS-CoV-2 findings observed with Immuron’s commercial hyper-immune colostrum.
- The agreement is for further research and identification of the inhibitory substance/s in the Company’s marketed products.
ASX and NASDAQ listed biopharmaceutical company Immuron Limited (ASX: IMC) has entered a new research services agreement with the Monash University. The agreement covers the development of new assays to evaluate the efficacy of IMM-124E.
IMM-124E is the active pharmaceutical ingredient (API) that is used for manufacturing Travelan® and Protectyn®.
Following this announcement, IMC shares jumped and traded at A$0.260, up by 8.33% (at AEDT 10:39 AM) on 15 December 2020. The Company’s market capitalisation stood at A$54.44 million.
About Immuron Limited
Australian dual-listed biopharmaceutical company Immuron Limited is focused on the development and commercialisation of orally delivered targeted polyclonal antibodies to treat inflammatory mediated as well as infectious indications. The Company has a novel and safe technology platform with one commercial asset generating revenue.
New Research Services Agreement with Monash University
Immuron disclosed the new research agreement in a market update on its progress towards further development of the antiviral activity of IMM-124E.
©Kalkine Group 2020
INTERESTING READ: Immuron shares leapfrog after promising update on diarrhea vaccine
The Hyper-immune Bovine Colostrum of Immuron is used for the manufacturing of Travelan® and Protectyn®. The Hyper-immune Bovine Colostrum had demonstrated antiviral activity against the SARS-CoV-2 virus (the virus causing COVID-19) in laboratory studies.
The Company disclosed that this new research agreement has been executed to further research and identify the inhibitory substance/s in the marketed products of Immuron, including IMM-124E.
Detailed discussion on Research and Development
Dr Melanie Hutton and Professor Dena Lyras, Deputy Director, Biomedicine Discovery Institute and Deputy Head, Department of Microbiology will lead the research team.
The study will use two new recombinant reagents, the SARS-CoV-2 Spike protein, a receptor-binding domain protein, and an antibody-positive human serum sample secured from the Peter Doherty Institute for Infection and Immunity Melbourne.
Professor Lyras said-
The Company has been engaged with local, national, as well as international research collaborators for advancing this research and for the further characterisation of the neutralisation activity of novel coronavirus observed with the commercial hyper-immune colostrum.
Immuron’s commercial hyper-immune colostrum is used to manufacture the over-the-counter (OTC) digestive and gastrointestinal health immune supplements Protectyn® and Travelan®.
Drug Development Plan for IMM-124E
Besides, the Company is planning to register Travelan® with the US Food and Drug Administration (FDA)` as a drug to reduce the risk of Travelers’ Diarrhea (TD) in travellers to endemic areas.